SAN DIEGO, March 01, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the "Company" or "Fate Therapeutics") (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that the Company will participate in the following upcoming investor conferences:
TD Cowen's 44th Annual Health Care Conference on Wednesday, March 6th, 2024 at 9:10 AM ET in Boston, Massachusetts
- Participating in an industry panel and hosting 1x1 investor meetings
Leerink Global Biopharma Conference on Monday, March 11th, 2024 at 2:00 PM ET in Miami, Florida